Antiaging Efforts in Endocrine Aspects

Article information

J Korean Med Assoc. 2007;50(3):234-239

Publication date (electronic) : 2007 March 31

doi : https://doi.org/10.5124/jkma.2007.50.3.234

Department of Internal Medicine, Hallym University College of Medicine, Korea. yooyoo1@kornet.net

Abstract

Although there are many definitions of successful aging in gerontology, no single consensus thereon exists. Successful aging is defined not by longevity alone but also by sufficient wellbeing (in multiple domains) to sustain a capacity for functioning adequately in changing circumstances. The determinants of such well-being and functional status are manifold and include the genetic endowment, physical environment, social environment, population and individual responses to challenges, the occurrence of disease, availability and effectiveness of health care, and personal prosperity. Rowe and Kahn defined it as including three main components: low probability of disease and disease-related disability, high cognitive and physical functional capacity, and active engagement with life. Growth hormone and testosterone seem to play a role in the physical decline that occurs during aging. In addition, both serum IGF-I and testosterone concentrations are related to the presence of atherosclerosis. Furthermore, the effect of growth hormone and testosterone replacement on the quality of life has hardly been examined in the elderly population.

Keywords: Antiaging; Melatonin; DHEA; GH; Sex hormone

References

1. Yoo HJ. Antiaging Clinic 1999. Seoul: Yul Eum Sa;

2. Rowe JW, Kahn RL. Human aging: usual and successful. Science 1987. 237143–149.

3. Yoo HJ. Endocrine disorders in elderly. J Korean Med Assoc 2005. 48125–131.

4. Boonen S, Lesaffre E, Dequeker J, Aerssens J, Nijs J, Pelemans W, Bouillon R. Relationship between baseline insulinlike growth factor-I(IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. J Am Geriatr Soc 1996. 441301–1306.

5. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996. 13352–356.

6. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. J Endocr 1996. 43S. 57–63.

7. van den Beld A, Huhtaniemi IT, Petterson KS, Pols HA, Grobbee DE, de Jong FH, Lamberts SW. Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. JCEM 1999. 841334–1339.

8. van den Beld A, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. JCEM 2000. 853276–3282.

9. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioacailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999. 84573–577.

10. Karlberg J, Mattsson LA, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet Gynecol Scand 1995. 74367–372.

11. Howell S, Shalet S. Teasterone deficiency and replacement. Horm Res 2001. 56S. 83–92.

12. van den Beld A, Lamberts SW. In : Chanson P, et al, ed. Prediction of death in elderly men: Endocrine factors. Endocrine aspects of successful aging: Genes, hormones and life styles 2003. Berlin: Springer; 217–227.

13. Park CS, Yoo HJ, Lee KY. Plasma dehydroepiandrosterone-sulfate (DHEA-S) and DHEA-S / Cortisol ratio by aging in Korean. J Kor Endocr Society 1997. 1263–67.

14. Yoo HJ. DHEA and Melatonin. J Kor Endocr Society 1997. S. 161–170.

15. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999. 841527–1533.

16. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Forette F, et al. DHEA, DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobio-medical issue. Proc Natl Acad Sci USA 2000. 974297–4284.

17. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. DHEA replacement in women with adrenal insufficiency. N Engl J Med 1999. 3411013–1020.

18. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B. DHEA supplementation in healthy men with an age-related decline of DHEA secretion. J Clin Endocrinol Metab 2001. 864686–4692.

19. Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 1993. 75875–886.

20. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006. 3551647–1655.

21. Stewart PM. Aging and fountain-of-youth hormones. NEJM 2006. 3551724–1725.

22. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, A and IGFB-I levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998. 18277–282.

23. van den Beld A, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003. 15725–31.

Article information Continued

Figure 1

Concept of successful aging(by Rowe and Kahn)